J & J plans to buy actelion, a Swiss pharmaceutical company, for $20 billion

Source: 36 krypton 2016-11-29 Johnson & Johnson recently said it was in contact with actelion, a Swiss pharmaceutical company, to discuss the acquisition Actelion is the largest biotechnology company in Europe with a valuation of nearly $20 billion The acquisition may help expand the product line and develop a variety of drugs Actelion confirmed J & J's bid, but said it was not certain a deal would be reached Johnson & Johnson is headquartered in Brunswick, New Jersey Its main product REMICADE is about to face competition from Pfizer for cheaper drugs REMICADE, an autoimmune treatment drug, sold $4.5 billion in U.S sales last year Pfizer said it plans to begin selling its similar drug, infractra, in the US this month Johnson & Johnson said it currently has several new drugs under development that could make up for its lost revenue Actelion's deal will help Johnson & Johnson quickly make up for its lost sales Actelion has been committed to the research and development of drugs for rare diseases, and due to the low price pressure of drugs for rare diseases, it has become an attractive acquisition target The company's sales for the first nine months of this year were CHF 1.785 billion ($1.8 billion) Actelion's opsumit and uptravi are both used to treat life-threatening diseases caused by pulmonary hypertension According to analysts' forecast, the total sales of the two drugs will exceed 4.6 billion US dollars by 2020, far higher than the expectation of 1.4 billion US dollars this year It is understood that actelion's valuation may exceed $20 billion Actelion's shares rose nearly 17 percent to 182.50 Swiss francs ($184.03) after Friday's listing on the six Swiss stock exchange Actelion was founded in 1997, and since its IPO in 2000, its valuation has risen all the way Last year, the company reported revenue of CHF 2.05 billion and profit of CHF 551.9 million Johnson & Johnson has a market value of more than $300 billion and overseas cash of nearly $40 billion Johnson & Johnson's biggest deal to date has been the $21 billion acquisition of synths, a trauma equipment maker, in 2011 In September, Johnson & Johnson purchased Abbott's eye care business for $4.3 billion Rare diseases are not the focus of Johnson & Johnson's business, but actelion's best-selling drugs can complement Johnson & Johnson's heart drugs Large pharmaceutical companies such as Pfizer and Sanofi have listed rare diseases as their priority research and development direction Because with the deep understanding of the molecular structure of the root cause of the disease, new treatment methods will be developed And health insurance companies are willing to pay high costs for it, because after all, only a few members need it.